Atea Pharmaceuticals, Inc.
AVIR
$3.07
$0.010.33%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 9.98% | -14.16% | |||
| Gross Profit | -9.98% | 14.16% | |||
| SG&A Expenses | 20.94% | -9.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.89% | -12.60% | |||
| Operating Income | -13.89% | 12.60% | |||
| Income Before Tax | -7.74% | 23.22% | |||
| Income Tax Expenses | -0.44% | -7.00% | |||
| Earnings from Continuing Operations | -7.68% | 23.13% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.68% | 23.13% | |||
| EBIT | -13.89% | 12.60% | |||
| EBITDA | -13.94% | 12.63% | |||
| EPS Basic | -7.62% | 23.28% | |||
| Normalized Basic EPS | -19.64% | 14.42% | |||
| EPS Diluted | -7.62% | 23.28% | |||
| Normalized Diluted EPS | -19.64% | 14.42% | |||
| Average Basic Shares Outstanding | 0.05% | 0.20% | |||
| Average Diluted Shares Outstanding | 0.05% | 0.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
